Brief: SynAct Pharma Receives IND Clearance From FDA
Nov 1 (Reuters) - SynAct Pharma AB SYNACT.ST :
* SYNACT PHARMA RECEIVES IND CLEARANCE FROM THE FDA FOR
PHASE 2A/B
TRIAL OF AP1189 IN RA
Source text for Eikon: ID:nMFN9M0Hwk
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development